Apic Bio, Inc.

Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene

UniQure is to cut its workforce by 28% and drop more than half its research and technology projects in an effort to streamline and focus its gene therapy-based business. The Amsterdam, Netherlands-he

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Dragonfly Takes Back IL-12 Immunotherap

Series E Brings $18m To 3-V Biosciences 3-V Biosciences Inc. , which is developing drugs for cancer and nonalcoholic steatohepatitis (NASH), raised $18m through its Series E round. New investor and p